Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT00642733
STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT00642850
A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 127
- Registration Number
- NCT00642967
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 116
- Registration Number
- NCT00623870
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00623597
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 235
- Registration Number
- NCT00623428
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 123
- Registration Number
- NCT00623805
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 323
- Registration Number
- NCT00616798
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Optimized background ARV therapy
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00615134
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 219
- Registration Number
- NCT00614471
© Copyright 2025. All Rights Reserved by MedPath